KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD

American Journal of Kidney Diseases

Volumn 62, Issue 2, 2013, Pages 201-213

  Taler, Sandra J ^a   Agarwal, Rajiv ^b   Bakris, George L ^c   Flynn, Joseph T ^d,e   Nilsson, Peter M ^f   Rahman, Mahboob ^g   Sanders, Paul W ^h,i   Textor, Stephen C ^a   Weir, Matthew R ^j   Townsend, Raymond R ^k  

^a MAYO CLINIC   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f LUND UNIVERSITY   (Sweden)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h BIRMINGHAM VA MEDICAL CENTER   (United States)

ⁱ University of Alabama at Birmingham   (United States)

^j UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

blood pressure; guideline; Kidney Disease: Improving Global Outcomes (KDIGO)

Indexed keywords

ALBUMINURIA; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIABETES MELLITUS; DIET SUPPLEMENTATION; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; PROTEINURIA; RECIPIENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING;

EID: 84880644910     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.03.018     Document Type: Article

References (43)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Kidney Int Suppl 2 2012 337 414
2. National Kidney Foundation K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease Am J Kidney Dis 43 5 2004 S1 S290 (suppl 1)
3. G.H. Guyatt, A.D. Oxman, H.J. Schunemann, P. Tugwell, A. Knottnerus GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology J Clin Epidemiol 64 4 2011 380 382
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Kidney Int Suppl 3 2013 1 150
5. S.D. Persell Prevalence of resistant hypertension in the United States, 2003-2008 Hypertension 57 6 2011 1076 1080
6. D.A. Calhoun, D. Jones, S. Textor Resistant hypertension: diagnosis, evaluation, and treatment A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 6 2008 1403 1419
7. F.M. Sacks, L.P. Svetkey, W.M. Vollmer Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet N Engl J Med 344 2001 3 10
8. Institute of Medicine Strategies to reduce sodium intake in the United States 2010 www.iom.edu/sodiumstrategies Accessed December 12, 2012
9. H.L. Heerspink, E. Ritz Sodium chloride intake: is lower always better? J Am Soc Nephrol 23 7 2012 1136 1139
10. G. Chiva-Blanch, M. Urpi-Sarda, E. Ros Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: short communication Circ Res 111 8 2012 1065 1068
11. National Institute for Health and Clinical Excellence (NICE) Hypertension: clinical management of primary hypertension in adults 2006 http://publications.nice.org.uk/hypertension-cg127 Accessed December 17, 2012
12. L.Y. Agodoa, L. Appel, G.L. Bakris Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial JAMA 285 21 2001 2719 2728
13. D.A. Sica The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned? J Clin Hypertens (Greenwich) 5 2 2003 159 167
14. W.S. Aronow, J.L. Fleg, C.J. Pepine ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension J Am Coll Cardiol 57 20 2011 2037 2114
15. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 UK Prospective Diabetes Study Group BMJ 317 7160 1998 703 713
16. J. Perk, G. De Backer, H. Gohlke European guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J 33 13 2012 1635 1701
17. L. Hansson, A. Zanchetti, S.G. Carruthers Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial HOT Study Group Lancet 351 9118 1998 1755 1762
18. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 suppl 1 2013 S11 S66
19. C.A. Peralta, K.C. Norris, S. Li Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP) Arch Intern Med 172 1 2012 41 47
20. Y. Slinin, A. Ishani, T. Rector Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline Am J Kidney Dis 60 5 2012 747 769
21. J.F. Mann, R.E. Schmieder, M. McQueen Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET Study): a multicentre, randomised, double-blind, controlled trial Lancet 372 9638 2008 547 553
22. S. Wood ALTITUDE halted: adverse events when aliskiren added to ACE, ARB therapy 2011 http://www.theheart.org/article/1331173.do Accessed December 17, 2012
23. H.H. Parving, B.M. Brenner, J.J. McMurray Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) J Renin Angiotensin Aldosterone Syst 13 3 2012 387 393
24. L.F. Fried, W. Duckworth, J.H. Zhang Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D) Clin J Am Soc Nephrol 4 2 2009 361 368
25. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients Am J Transplant 9 suppl 3 2009 S1 S155
26. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents Pediatrics 114 2 2004 555 576 (suppl 4th report)
27. E. Lurbe, R. Cifkova, J.K. Cruickshank Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension J Hypertens 27 9 2009 1719 1742
28. E. Wuhl, A. Trivelli, S. Picca Strict blood-pressure control and progression of renal failure in children N Engl J Med 361 17 2009 1639 1650
29. S.L. Furth, J.T. Flynn, C. Pierce Lower systolic BP associated with slower CKD progression in the CKiD Study J Am Soc Nephrol 21 2010 551A
30. E. Urbina, B. Alpert, J. Flynn Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young and the Council for High Blood Pressure Research Hypertension 52 3 2008 433 451
31. W.P. Welch, W. Yang, P. Taylor-Zapata, J.T. Flynn Antihypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens (Greenwich) 14 6 2012 388 395
32. J.T. Flynn, M. Mitsnefes, C. Pierce Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study Hypertension 52 4 2008 631 637
33. C.T. White, C.F. Macpherson, R.M. Hurley, D.G. Matsell Antiproteinuric effects of enalapril and losartan: a pilot study Pediatr Nephrol 18 10 2003 1038 1043
34. R.P. Woroniecki, J.T. Flynn How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists Pediatr Nephrol 20 6 2005 791 797
35. W.O. Cooper, S. Hernandez-Diaz, P.G. Arbogast Major congenital malformations after first-trimester exposure to ACE inhibitors N Engl J Med 354 23 2006 2443 2451
36. J. Samuels, D. Ng, J.T. Flynn Ambulatory blood pressure patterns in children with chronic kidney disease Hypertension 60 1 2012 43 50
37. A.V. Chobanian, G.L. Bakris, H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 19 2003 2560 2572
38. G.W. Somes, M. Pahor, R.I. Shorr, W.C. Cushman, W.B. Applegate The role of diastolic blood pressure when treating isolated systolic hypertension Arch Intern Med 159 17 1999 2004 2009
39. The Systolic Blood Pressure Intervention Trial. Wake Forest University http://www.sprinttrial.org Accessed December 10, 2012
40. P. Tricoci, J.M. Allen, J.M. Kramer, R.M. Califf, S.C. Smith Jr Scientific evidence underlying the ACC/AHA clinical practice guidelines JAMA 301 8 2009 831 841
41. NKF & FDA Workshop on GFR Decline as a Clinical Endpoint for Clinical Trials in CKD. National Kidney Foundation http://www.kidney.org/news/newsroom/ nr/Earlier-Endpoints-Proposed-for-Clinical-Trials-in-CKD.cfm? utm-source-nkfhome&utm-medium-static&utm-campaign-FDA Accessed December 17, 2012
42. J.D. Kopple, X. Zhu, N.L. Lew, E.G. Lowrie Body weight-for-height relationships predict mortality in maintenance hemodialysis patients Kidney Int 56 3 1999 1136 1148
43. W.C. Cushman, G.W. Evans, R.P. Byington Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 17 2010 1575 1585